Shares of ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB - Get Free Report) crossed above its 50-day moving average during trading on Friday . The stock has a 50-day moving average of $53.40 and traded as high as $56.15. ProShares Ultra Nasdaq Biotechnology shares last traded at $55.17, with a volume of 9,601 shares traded.
ProShares Ultra Nasdaq Biotechnology Stock Performance
The firm's 50-day moving average is $53.32 and its two-hundred day moving average is $59.41.
ProShares Ultra Nasdaq Biotechnology Increases Dividend
The company also recently announced a dividend, which was paid on Tuesday, December 31st. Shareholders of record on Monday, December 23rd were issued a dividend of $0.3964 per share. The ex-dividend date of this dividend was Monday, December 23rd. This is a boost from ProShares Ultra Nasdaq Biotechnology's previous dividend of $0.15.
Hedge Funds Weigh In On ProShares Ultra Nasdaq Biotechnology
Hedge funds and other institutional investors have recently made changes to their positions in the company. Tower Research Capital LLC TRC boosted its position in ProShares Ultra Nasdaq Biotechnology by 31.2% during the fourth quarter. Tower Research Capital LLC TRC now owns 5,326 shares of the exchange traded fund's stock worth $270,000 after acquiring an additional 1,266 shares during the last quarter. Crowley Wealth Management Inc. purchased a new position in ProShares Ultra Nasdaq Biotechnology in the 4th quarter worth approximately $51,000. Finally, Jane Street Group LLC boosted its holdings in shares of ProShares Ultra Nasdaq Biotechnology by 8.4% during the 3rd quarter. Jane Street Group LLC now owns 4,803 shares of the exchange traded fund's stock worth $306,000 after purchasing an additional 374 shares during the last quarter.
About ProShares Ultra Nasdaq Biotechnology
(
Get Free Report)
ProShares Ultra Nasdaq Biotechnology (the Fund) seeks daily investment results, before fees and expenses, that correspond to twice (200%) the daily performance of the Index. The return of the Fund for a period longer than a single trading day will be the result of each day's returns compounded over the period, which will very likely differ from the inverse of the return of the Dow Jones United States Basic Materials Index (the Index) for that period.
Read More
Before you consider ProShares Ultra Nasdaq Biotechnology, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ProShares Ultra Nasdaq Biotechnology wasn't on the list.
While ProShares Ultra Nasdaq Biotechnology currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
